Multicentre study to determine the Etest epidemiological cut-off values of antifungal drugs in Candida spp. and Aspergillus fumigatus species complex

Clinical Microbiology and Infection

Volumn 25, Issue 12, 2019, Pages 1546-1552

  Salse M ^a   Gangneux, J P ^b   Cassaing, S ^c   Delhaes, L ^d   Fekkar, A ^e   Dupont, D ^f   Botterel, F ^g   Costa, D ^h   Bourgeois, N ⁱ   Bouteille, B ^j   Houze S ^k   Dannaoui, E ^l   Guegan, H ^b   Charpentier, E ^c   Persat, F ^f   Favennec, L ^h   Lachaud, L ⁱ   Sasso, M ^a  

^a UNIV MONTPELLIER   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITÉ LYON 1   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

ⁱ University de Montpellier   (France)

^j LIMOGES UNIVERSITY HOSPITAL   (France)

^k ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^l UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

Antifungal agents; Aspergillus; Candida; Epidemiological cut off values; Etest

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; EPSILOMETER TEST; FRANCE; FUNGUS ISOLATION; KLUYVEROMYCES MARXIANUS; MEYEROZYMA GUILLIERMONDII; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PICHIA KUDRIAVZEVII; PRIORITY JOURNAL; SPECIES COMPLEX; ANTIFUNGAL RESISTANCE; BIOASSAY; CLINICAL TRIAL; DISK DIFFUSION; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOSIS; RETROSPECTIVE STUDY;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CANDIDA; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, FUNGAL; ENDPOINT DETERMINATION; FRANCE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; RETROSPECTIVE STUDIES;

EID: 85066492357     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2019.04.027     Document Type: Article

References (30)

1. Dromer, F., Bretagne, S., Lortholary, O., Rapport annuel d'activité - centre National de référence Mycoses Invasives et Antifongiques. 2016, Institut Pasteur, Paris.
2. Ullmann, A.J., Aguado, J.M., Arikan-Akdagli, S., Denning, D.W., Groll, A.H., Lagrou, K., et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 24 (2018), e1–e38.
3. Cornely, O.A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B.J., Lortholary, O., et al. ESCMID Guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18 (2012), 19–37.
4. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Fourth informational supplement M27-S4, 2012, CLSI, Wayne, PA.
5. Arendrup, M.C., Cuenca-Estrella, M., Lass-Flörl, C., Hope, W.W., Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat 16 (2013), 81–95.
6. European Committee on Antimicrobial Susceptibility Testing EUCAST. Antifungal_breakpoints_v_9.0_180212. 2018, EUCAST.
7. Turnidge, J., Kahlmeter, G., Kronvall, G., Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12 (2006), 418–425.
8. Lockhart, S.R., Ghannoum, M.A., Alexander, B.D., Establishment and use of epidemiological cutoff values for molds and yeasts by use of the Clinical and Laboratory Standards Institute M57 Standard. J Clin Microbiol 55 (2017), 1262–1268.
9. Espinel-Ingroff, A., Turnidge, J., The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds. Rev Iberoam Micol 33 (2016), 63–75.
10. Espinel-Ingroff, A., Turnidge, J., Alastruey-Izquierdo, A., Dannaoui, E., Garcia-Effron, G., Guinea, J., et al. Posaconazole MIC distributions for Aspergillus fumigatus species complex by four methods: impact of cyp51A mutations on estimation of epidemiological cutoff values. Antimicrob Agents Chemother 62 (2018), e01916–e01917.
11. Espinel-Ingroff, A., Turnidge, J., Alastruey-Izquierdo, A., Botterel, F., Canton, E., Castro, C., et al. Method-dependent epidemiological cutoff values (ECVs) for detection of triazole resistance in Candida and Aspergillus species for the SYO colorimetric broth and Etest agar diffusion methods. Antimicrob Agents Chemother, 63, 2018 e01651-18.
12. Espinel-Ingroff, A., Pfaller, M.A., Bustamante, B., Canton, E., Fothergill, A., Fuller, J., et al. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 58 (2014), 2006–2012.
13. Espinel-Ingroff, A., Arendrup, M., Cantón, E., Cordoba, S., Dannaoui, E., García-Rodríguez, J., et al. Multicenter study of method-dependent epidemiological cutoff values for detection of resistance in Candida spp. and Aspergillus spp. to Amphotericin B and echinocandins for the Etest agar diffusion method. Antimicrob Agents Chemother, 61, 2016 e01792-16.
14. Meletiadis, J., Curfs-Breuker, I., Meis, J.F., Mouton, J.W., In vitro antifungal susceptibility testing of Candida isolates with the EUCAST methodology, a new method for ECOFF determination. Antimicrob Agents Chemother, 61, 2017 e02372-16.
15. Pfaller, M.A., Diekema, D.J., Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 50 (2012), 2846–2856.
16. Pfaller, M.A., Espinel-Ingroff, A., Bustamante, B., Canton, E., Diekema, D.J., Fothergill, A., et al. Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother 58 (2014), 916–922.
17. Clinical and Laboratory Standards Institute. Epidemiological cutoff values for antifungal susceptibility testing M59. 2016, CLSI, Wayne, PA.
18. Espinel-Ingroff, A., Fothergill, A., Fuller, J., Johnson, E., Pelaez, T., Turnidge, J., Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document). Antimicrob Agents Chemother 55 (2011), 2855–2859.
19. Pfaller, M.A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D.J., et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 50 (2012), 2040–2046.
20. biomérieux, S.A., Etest antifungal susceptibility testing for in vitro diagnostic use package insert. 2013, Marcy l'Étoile: bioMérieux.
21. biomérieux, S.A., Summary of etest. Performance interpretative criteria and quality control ranges. 2018, Marcy l'Étoile: bioMérieux.
22. Howard, S.J., Lass-Flörl, C., Cuenca-Estrella, M., Gomez-Lopez, A., Arendrup, M.C., Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob Agents Chemother 57 (2013), 5426–5431.
23. European Committee on Antimicrobial Susceptibility Testing EUCAST. EUCAST Antimicrobial wild type distributions of microorganisms. Available at: https://MicEucastOrg/Eucast2/2019. https://mic.eucast.org/Eucast2/(accessed 11 December 2018).
24. Morris, A.J., Rogers, K., McKinney, W.P., Roberts, S.A., Freeman, J.T., Antifungal susceptibility testing results of New Zealand yeast isolates, 2001–2015: impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species. J Glob Antimicrob Resist 14 (2018), 72–77.
25. Pfaller, M.A., Diekema, D.J., Jones, R.N., Castanheira, M., Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria. J Clin Microbiol 52 (2014), 3223–3229.
26. Alexander, B.D., Byrne, T.C., Smith, K.L., Hanson, K.E., Anstrom, K.J., Perfect, J.R., et al. Comparative evaluation of etest and Sensititre YeastOne panels against the clinical and laboratory standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol 45 (2007), 698–706.
27. Metin, D.Y., Hilmioglu-Polat, S., Samlioglu, P., Doganay-Oflazoglu, B., Inci, R., Tumbay, E., Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates. Mycopathologia 172 (2011), 187–199.
28. Alastruey-Izquierdo, A., Alcazar-Fuoli, L., Cuenca-Estrella, M., Antifungal susceptibility profile of cryptic species of Aspergillus. Mycopathologia 178 (2014), 427–433.
29. Aigner, M., Erbeznik, T., Gschwentner, M., Lass-Flörl, C., Etest and Sensititre YeastOne susceptibility testing of echinocandins against Candida species from a single center in Austria. Antimicrob Agents Chemother 61 (2017), e00512–e00517.
30. Dannaoui, E., Paugam, A., Develoux, M., Chochillon, C., Matheron, J., Datry, A., et al. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories. Clin Microbiol Infect 16 (2010), 863–869.